Schedule 13G - Passive Investments
NASDAQ
Lincoln Alternative Strategies LLC has reported a 9.9% beneficial ownership stake in XORTX Therapeutics Inc., holding 572,470 common shares.
NASDAQ
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Reduce Stake in XORTX Therapeutics Below 5% Threshold
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership of XORTX Therapeutics Inc. common shares to 4.99%.
Worse than expected
NASDAQ
Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of XORTX Therapeutics Inc.'s common shares as of December 31, 2024.